18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab

Neuro-Oncology

Volumn 14, Issue 8, 2012, Pages 1079-1089

  Harris, Robert J ^a   Cloughesy, Timothy F ^a   Pope, Whitney B ^a   Nghiemphu, Phioanh L ^a   Lai, Albert ^a   Zaw, Taryar ^a   Czernin, Johannes ^a   Phelps, Michael E ^a   Chen, Wei ^a   Ellingson, Benjamin M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

18F FDOPA; 18F FLT, glioblastoma; Bevacizumab; PRMs

Indexed keywords

6 FLUORODOPA F 18; BEVACIZUMAB; FLUORO 3 DEOXY 3 LEVO FLUOROTHYMIDINE F 18; IRINOTECAN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; FLUORINE; MONOCLONAL ANTIBODY;

ARTICLE; BRAIN MAPPING; BRAIN SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DRUG RESPONSE; GLIOMA; HUMAN; IMAGE ANALYSIS; IMAGE ENHANCEMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; RECEIVER OPERATING CHARACTERISTIC; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME; AREA UNDER THE CURVE; BRAIN TUMOR; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; METHODOLOGY; MORTALITY; PROGNOSIS; SCINTISCANNING; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; FLUORINE RADIOISOTOPES; GLIOMA; HUMANS; KAPLAN-MEIER ESTIMATE; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84864683637     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos141     Document Type: Article

References (48)

1. Weil RJ. Glioblastoma multiforme-treating a deadly tumor with both strands of RNA. PLoS Med. 2006;3(1):e31.
2. Chamberlain MC. Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas. Cancer. 2010;116(17):3988-3999.
3. Nghiemphu PL, Liu W, Lee Y, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: A single-institution experience. Neurology. 2009;72(14):1217-1222.
4. Ellingson BM, Cloughesy TF, Lai A, et al. Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011;13(10):1151-1161.
5. Ellingson BM, Cloughesy TF, Lai A, et al. Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab. J Neurooncol. 2012;106(1):111-119.
6. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Mischel PS, Pope WB. Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011;13(4):401-409.
7. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Pope WB. Cell invasion, motility, and proliferation level estimate (CIMPLE) maps derived from serial diffusion MR images in recurrent glioblastoma treated with bevacizumab. J Neurooncol. 2011;105(1):91-101.
8. Pope WB, Lai A, Mehta R, et al. Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. AJNR Am J Neuroradiol. 2011;32(5):882-889.
9. Pope WB, Kim HJ, Huo J, et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology. 2009;252(1):182-189.
10. HongIK,KimJH,RaYS,Kwon do H,OhSJ,KimJS.DiagnosticUsefulness of. 3-Deoxy-3-[18F]Fluorothymidine Positron Emission Tomography in Recurrent Brain Tumor. J Comput Assist Tomogr. 2011;35(6):679-684.
11. Chen W, Cloughesy T, Kamdar N, et al. Imaging proliferation in brain tumors with 18F-FLT PET: Comparison with 18F-FDG. J Nucl Med. 2005;46(6):945-952.
12. Gonzalez-Forero M, Prieto E, Dominguez I, Vigil C, Penuelas I, Arbizu J. [Dual time point 18F-FDOPA PET as a tool for characterizing brain tumors]. Rev Esp Med Nucl. 2011;30(2):88-93.
13. Schwarzenberg J, Czernin J, Cloughesy TF, et al. 3?-Deoxy-3?-18F- Fluorothymidine PET and MRI for Early Survival Predictions in Patients with Recurrent Malignant Glioma Treated with Bevacizumab. J Nucl Med. 2012;53(1):29-36.
14. Chen W, Delaloye S, Silverman DH, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: A pilot study. J Clin Oncol. 2007;25(30):4714-4721.
15. Fueger BJ,CzerninJ,CloughesyT, etal.Correlationof6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. J NuclMed. 2010;51(10):1532-1538.
16. Ledezma CJ, Chen W, Sai V, et al. 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: Initial experience. Eur J Radiol. 2009;71(2):242-248.
17. Chen W, Silverman DH, Delaloye S, et al. 18F-FDOPA PET imaging of brain tumors: Comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med. 2006;47(6):904-911.
18. Namavari M, Bishop A, Satyamurthy N, Bida G, Barrio JR. Regioselective radiofluorodestannylation with [18F]F2 and [18F]CH3COOF: A high yield synthesis of 6-[18F]Fluoro-L-dopa. Int J Rad Appl Instrum A. 1992;43(8):989-996.
19. Bishop A, Satyamurthy N, Bida G, Hendry G, Phelps M, Barrio JR. Proton irradiation of [18O]O2: Production of [18F]F2 and [18F]F2 + [18F] OF2. Nucl Med Biol. 1996;23(3):189-199.
20. Blocher A, Kuntzsch M, Wei R, Machulla HJ. Synthesis and labeling of 5?-O-(4,4?-dimethoxytrityl)-2,3?-anhydrothymidine for [F-18]FLT preparation. J Radioanal Nucl Chem. 2002;251(1):55-58.
21. Bergstrom M, Litton J, Eriksson L, Bohm C, Blomqvist G. Determination of object contour from projections for attenuation correction in cranial positron emission tomography. J Comput Assist Tomogr. 1982;6(2):365-372.
22. Ellingson BM, Malkin MG, Rand SD, et al. Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging. 2010;31(3):538-548.
23. Brant-Zawadzki M, Norman D, Newton TH, et al. Magnetic resonance of the brain: The optimal screening technique. Radiology. 1984;152(1):71-77.
24. Byrne TN. Imaging of gliomas. Semin Oncol. 1994;21(2):162-171.
25. Husstedt HW, Sickert M, Kostler H, Haubitz B, Becker H. Diagnostic value of the fast-FLAIR sequence in MR imaging of intracranial tumors. Eur Radiol. 2000;10(5):745-752.
26. Tsuchiya K, Mizutani Y, Hachiya J. Preliminary evaluation of fluidattenuated inversion-recovery MR in the diagnosis of intracranial tumors. AJNR Am J Neuroradiol. 1996;17(6):1081-1086.
27. Essig M, Hawighorst H, Schoenberg SO, et al. Fast fluid-attenuated inversion-recovery (FLAIR) MRI in the assessment of intraaxial brain tumors. J Magn Reson Imaging. 1998;8(4):789-798.
28. Lewander R, Bergstrom M, Bergvall U. Contrast enhancement of cranial lesions in computed tomography. Acta Radiol Diagn (Stockh). 1978;19(4):529-552.
29. Greene GM, Hitchon PW, Schelper RL, Yuh W, Dyste GN. Diagnostic yield in CT-guided stereotactic biopsy of gliomas. J Neurosurg. 1989;71(4):494-497.
30. Kelly PJ, Daumas-Duport C, Kispert DB, Kall BA, Scheithauer BW, Illig JJ. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg. 1987;66(6):865-874.
31. Kelly PJ. Computed tomography and histologic limits in glial neoplasms: Tumor types and selection for volumetric resection. Surg Neurol. 1993;39(6):458-465.
32. Earnest FT, Kelly PJ, Scheithauer BW, et al. Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology. 1988;166(3):823-827.
33. Watanabe M, Tanaka R, Takeda N. Magnetic resonance imaging and histopathology of cerebral gliomas. Neuroradiology. 1992;34(6): 463-469.
34. Macdonald DR, Cascino TL, Schold SC, Jr., Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277-1280.
35. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neurooncology working group. J Clin Oncol. 2010;28(11):1963-1972.
36. Vingerhoets FJ, Snow BJ, Schulzer M, et al. Reproducibility of fluorine-18-6-fluorodopa positron emission tomography in normal human subjects. J Nucl Med. 1994;35(1):18-24.
37. de LangenAJ,Klabbers B, LubberinkM, et al.Reproducibility ofquantitative. 18F-3?-deoxy-3?-fluorothymidine measurements using positron emission tomography. Eur J Nucl MedMol Imaging. 2009;36(3):389-395.
38. Shields AF, Lawhorn-Crews JM, Briston DA, et al. Analysis and reproducibility of 3?-Deoxy-3?-[18F]fluorothymidine positron emission tomography imaging in patients with non-small cell lung cancer. Clin Cancer Res. 2008;14(14):4463-4468.
39. Muzi M, Spence AM, O'Sullivan F, et al. Kinetic analysis of 3?-deoxy-3?-18F-fluorothymidine in patients with gliomas. J Nucl Med. 2006;47(10):1612-1621.
40. Huang SC, Yu DC, Barrio JR, et al. Kinetics and modeling of L-6-[18F]fluoro-dopa in human positron emission tomographic studies. J Cereb Blood Flow Metab. 1991;11(6):898-913.
41. Tripathi M, Sharma R, D'Souza M, et al. Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas. Clin Nucl Med. 2009;34(12):878-883.
42. Dowson N, Bourgeat P, Rose S, et al. Joint factor and kinetic analysis of dynamic FDOPA PET scans of brain cancer patients. Med Image Comput Comput Assist Interv. 2010;13(Pt 2):185-192.
43. Colavolpe C, Chinot O, Metellus P, et al. FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan. Neuro Oncol. 2012;14(5):649-657.
44. Cher LM, Murone C, Lawrentschuk N, et al. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. J Nucl Med. 2006;47(3):410-418.
45. Kreisl TN, Zhang W, Odia Y, et al. A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro Oncol. 2011;13(10):1143-1150.
46. Garnett S, Firnau G, Nahmias C, Chirakal R. Striatal dopamine metabolism in living monkeys examined by positron emission tomography. Brain Res. 1983;280(1):169-171.
47. Garnett ES, Firnau G, Nahmias C. Dopamine visualized in the basal ganglia of living man. Nature. 1983;305(5930):137-138.
48. Yee RE, Cheng DW, Huang SC, Namavari M, Satyamurthy N, Barrio JR. Blood-brain barrier and neuronal membrane transport of 6-[18F]fluoro-L-DOPA. Biochem Pharmacol. 2001;62(10): 1409-1415.